EVENT DETAILS
06/27/23 8:00 AM EDT
|
||
Title | In-Person KOL Breakfast: Protalix Presents following Elfabrio®’s Approvals for Fabry Disease in the US and the EU | |
Date and Time | 06/27/23 8:00 AM EDT | |
Description |
Hosted by Protalix Biotherapeutics (NYSE American: PLX) WHERE: Lotte Palace Hotel, New York Join us in-person for a KOL Breakfast with Protalix Biotherapeutics, discussing the recent FDA approval of Elfabrio® (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease. Event agenda: 1. Ankit Mehta, MD, FASN (Baylor University Medical Center) will discuss the opportunity for Elfabrio® to address the unmet needs in Fabry disease. A live question and answer session will follow the formal presentations. IMPORTANT INFORMATION Registration Information You are required to register in advance for the event. Q&A Information If you would like to ask a question during the live Q&A, please submit your request to questions@lifesciadvisors.com. |